Dendritic cell (DC)-based vaccines against cancer have been extensively developed over
the past two decades. Typically DC-based cancer immunotherapy entails loading patient …

Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable
development over recent decades. However, this field is currently in a state of flux toward …

Dendritic-cells (DCs) have received considerable attention as potential targets for the
development of anticancer vaccines. DC-based anticancer vaccination relies on patient …

Dendritic cells (DCs) occupy a central position in the immune system, orchestrating a wide
repertoire of responses that span from the development of self-tolerance to the elicitation of …

Dendritic cells (DCs) are the most potent professional antigen-presenting cells, capable of
initiating proper adaptive immune responses. Although tumor-infiltrating DCs are able to …

Advances in the understanding of the immunoregulatory functions of dendritic cells (DCs) in
animal models and humans have led to their exploitation as anticancer vaccines. Although …

Dendritic cells (DCs) are versatile elements of the immune system and are best known for
their unparalleled ability to initiate and modulate adaptive immune responses. During the …

The use of dendritic cells (DCs) for the generation of anti-tumour immunity has been the
focus of a vast array of scientific and clinical studies. The ability of DCs to present protein …

The discovery that dendritic cells (DC) play a key role in regulating antitumor immunity has
prompted considerable efforts in developing DC-based cancer vaccines for use in clinical …

Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective
antitumor immune response against tumor antigens and was first explored in a clinical trial …